MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 286 participants.

Also called NCT01299376

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 286 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01299376
Other papers using this trial's data
  • Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension Clinical and experimental hypertension (New York, N.Y. : 1993), 2015 DOI, PubMed 25271811

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01299376. Randomized; double masking; primary purpose treatment. Start 2011-01-24 (actual); primary completion 2011-11-16 (actual). Results posted on 2017-01-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)
Condition
Hypertension
Intervention (Drug)
L50/H12.5/A5
Intervention (Drug)
L50/H12.5
Intervention (Drug)
Placebo to L50/H12.5/A5
Intervention (Drug)
Placebo to L50/H12.5
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01299376
Content hash
1f1e6446361cdba8001c3f7a608c7d70075280b48f1e03db8582e94793cf180e